机构持仓方面，截止2025年9月30日，久远银海十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股305.37万股，相比上期减少156.95万股。金鹰科技创新股票A（001167）位居第四大流通 股东，持股300.00万股，为新进股东。南方中证1000ETF（512100）位居第六大流通股东，持股261.78 万股，相比上期减少1.61万股。易方达新常态混合（001184）退出十大流通股东之列。 责任编辑：小浪快报 1月5日，久远银海盘中上涨2.06%，截至13:43，报18.31元/股，成交9938.23万元，换手率1.36%，总市 值74.75亿元。 资金流向方面，主力资金净流入348.60万元，特大单买入845.32万元，占比8.51%，卖出294.23万元，占 比2.96%；大单买入1119.35万元，占比11.26%，卖出1321.84万元，占比13.30%。 截至11月28日，久远银海股东户数5.56万，较上期减少0.93%；人均流通股7280股，较上期增加0.94%。 2025年1月-9月，久远银海实现营业收入6.87亿元，同比增长2.83%；归母净利润4278.91万元，同比增长 ...

Core Viewpoint - The stock price of Tongchen Beijian has increased by 2.08% this year, with a market capitalization of 20.74 billion yuan as of January 5, 2025 [1][2]. Group 1: Stock Performance - As of January 5, 2025, the stock price reached 12.26 yuan per share, with a trading volume of 1.03 billion yuan and a turnover rate of 0.75% [1]. - The stock has experienced a decline of 0.89% over the last five trading days, but has increased by 3.20% over the last 20 days and 5.33% over the last 60 days [2]. Group 2: Company Overview - Tongchen Beijian, established on April 1, 2005, and listed on December 15, 2010, specializes in the research, production, and sales of dietary nutritional supplements [2]. - The company's revenue composition includes 38.02% from other products, 27.84% from capsules, 20.38% from tablets, and 13.76% from powders [2]. - The company is classified under the food and beverage industry, specifically in food processing and health products, with concepts including gene sequencing, vitamins, internet healthcare, cross-border e-commerce, and pharmaceutical e-commerce [2]. Group 3: Financial Performance - For the period from January to September 2025, Tongchen Beijian reported a revenue of 4.915 billion yuan, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders increased by 4.45% to 907 million yuan [2]. - Since its A-share listing, the company has distributed a total of 8.321 billion yuan in dividends, with 2.429 billion yuan distributed over the last three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders is 71,100, a decrease of 0.14% from the previous period, with an average of 15,762 circulating shares per person, down by 0.67% [2]. - The second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.8508 million shares, a decrease of 3.7464 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that Wanda Information's stock has experienced fluctuations, with a recent increase in price but an overall decline for the year [1] - As of December 31, Wanda Information's stock price was 6.49 yuan per share, with a market capitalization of 9.35 billion yuan [1] - The company has seen a net inflow of main funds amounting to 1.39 million yuan, with significant buying and selling activity from large orders [1] Group 2 - For the year 2025 (January to September), Wanda Information reported a revenue of 1.33 billion yuan, reflecting a year-on-year growth of 0.57%, while the net profit attributable to shareholders was -408 million yuan, showing a year-on-year increase of 27.07% [2] - The company has distributed a total of 292 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 9.78 million shares, a decrease of 2.64 million shares from the previous period [3]

Group 1 - The core viewpoint of the news is that Neusoft Corporation's stock has shown fluctuations, with a recent increase of 2.12% and a total market capitalization of 12.066 billion yuan [1] - As of December 31, Neusoft's stock price is 10.12 yuan per share, with a trading volume of 139 million yuan and a turnover rate of 1.16% [1] - Year-to-date, Neusoft's stock has decreased by 4.71%, with a recent 5-day increase of 2.02% and a 20-day increase of 0.60% [1] Group 2 - Neusoft's main business includes software technology, industry solutions, software products, platforms, services, and medical equipment, with 85.92% of revenue from proprietary software, products, and services [1] - As of September 30, Neusoft's revenue for the first nine months of 2025 was 7.491 billion yuan, a year-on-year increase of 8.72%, while net profit attributable to shareholders was 51.0818 million yuan, a decrease of 66.47% [2] - The company has distributed a total of 1.894 billion yuan in dividends since its A-share listing, with 332 million yuan distributed in the last three years [3] Group 3 - Neusoft's stockholder count reached 98,200 as of September 30, 2025, an increase of 8.72% from the previous period, while the average circulating shares per person decreased by 9.15% to 12,145 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 23.2244 million shares, a decrease of 21.662 million shares from the previous period [3]

Core Viewpoint - The stock of Yimikang has shown a positive trend with a year-to-date increase of 18.00%, despite a recent decline over the past 60 days [1][2]. Group 1: Stock Performance - As of December 30, Yimikang's stock price rose by 2.03% to 15.08 CNY per share, with a trading volume of 1.20 billion CNY and a turnover rate of 2.15%, resulting in a total market capitalization of 6.643 billion CNY [1]. - The stock has experienced a net inflow of 18.1565 million CNY from major funds, with significant buying activity from large orders [1]. - Over the past five trading days, the stock has increased by 2.31%, while it has decreased by 8.05% over the last 60 days [1]. Group 2: Company Overview - Yimikang Technology Group Co., Ltd. was established on September 12, 2002, and went public on August 3, 2011, specializing in green solutions for the entire lifecycle of digital infrastructure [2]. - The company operates in the computer equipment sector, focusing on data center solutions, and has a revenue composition of 100% from the information data field [2]. - As of September 30, the number of shareholders increased to 62,700, with an average of 5,958 circulating shares per person [2]. Group 3: Financial Performance - For the period from January to September 2025, Yimikang reported a revenue of 1.064 billion CNY, marking a year-on-year growth of 52.61%, and a net profit attributable to shareholders of 27.6472 million CNY, reflecting a significant increase of 273.71% [2]. - The company has distributed a total of 51.0709 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Yimikang's stock has shown a significant increase in price and trading activity, indicating positive market sentiment and investor interest [1][2]. - As of December 29, Yimikang's stock price rose by 2.12% to 14.94 CNY per share, with a total market capitalization of 6.581 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 16.90%, with a recent 4.92% rise over the last five trading days [1]. Group 2 - Yimikang Technology Group Co., Ltd. is based in Chengdu, Sichuan, and was established on September 12, 2002, with its listing date on August 3, 2011 [2]. - The company specializes in providing green solutions for the entire lifecycle of digital infrastructure, focusing on data centers and offering services across four main sectors: key equipment, intelligent engineering, IoT software, and smart services [2]. - For the period from January to September 2025, Yimikang achieved a revenue of 1.064 billion CNY, representing a year-on-year growth of 52.61%, and a net profit attributable to shareholders of 27.6472 million CNY, up 273.71% [2]. Group 3 - Yimikang has distributed a total of 51.0709 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - As of September 30, 2025, the number of shareholders increased to 62,700, with an average of 5,958 circulating shares per shareholder, a decrease of 4.65% from the previous period [2][3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 1.8998 million shares as a new shareholder [3].

Core Viewpoint - The stock of Sely Medical has experienced a significant increase of 198.75% this year, but has recently shown a decline in trading performance, with a drop of 3.66% over the last five trading days and 21.39% over the last 60 days [1]. Group 1: Stock Performance - As of December 26, Sely Medical's stock price is 21.57 CNY per share, with a market capitalization of 4.534 billion CNY [1]. - The company has seen a net outflow of 17.64 million CNY in principal funds, with large orders buying 11.94 million CNY and selling 30.74 million CNY [1]. - Sely Medical has appeared on the trading leaderboard 37 times this year, with the most recent appearance on August 26, where it recorded a net purchase of 146 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Sely Medical reported a revenue of 857 million CNY, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million CNY, down 55.72% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 27.07 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of December 10, the number of shareholders for Sely Medical is 70,400, a decrease of 11.22% from the previous period, with an average of 2,986 circulating shares per person, an increase of 12.64% [2]. - Notable institutional shareholders include Caixin Advantage Industry Rotation Mixed Fund, which increased its holdings by 58.48% to 1.2282 million shares, and new entrants such as GF Healthcare Stock A and others [3].

Core Viewpoint - The stock price of Tongrentang has shown a modest increase, with a notable rise in trading volume and a positive net inflow of funds, indicating investor interest in the company [1][2]. Group 1: Stock Performance - As of December 25, Tongrentang's stock price increased by 2.08%, reaching 12.28 CNY per share, with a trading volume of 1.25 billion CNY and a market capitalization of 20.774 billion CNY [1]. - Year-to-date, the stock price has risen by 5.01%, with a 2.68% increase over the last five trading days, a 0.49% increase over the last 20 days, and a 5.05% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Tongrentang reported a revenue of 4.915 billion CNY, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders was 907 million CNY, reflecting a year-on-year increase of 4.45% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tongrentang was 71,100, a slight decrease of 0.14% from the previous period, with an average of 15,762 circulating shares per person, down by 0.67% [2]. - The company has distributed a total of 8.321 billion CNY in dividends since its A-share listing, with 2.429 billion CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, the second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.851 million shares, a decrease of 3.746 million shares from the previous period [3]. - Hong Kong Central Clearing Limited is the fifth-largest shareholder, increasing its holdings by 2.712 million shares to 15.086 million shares [3].

Core Viewpoint - The stock of Sely Medical has experienced a significant increase of 193.77% this year, but has recently shown a decline in the short term, with a drop of 3.15% over the last five trading days and 23.71% over the last 60 days [1] Group 1: Stock Performance - As of December 25, Sely Medical's stock price is 21.21 CNY per share, with a market capitalization of 4.458 billion CNY [1] - The stock has seen a net outflow of 957,700 CNY in principal funds, with large orders buying 4.3736 million CNY (6.41% of total) and selling 5.3313 million CNY (7.81% of total) [1] - The company has appeared on the "Dragon and Tiger List" 37 times this year, with the most recent appearance on August 26, where it recorded a net purchase of 146 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Sely Medical reported a revenue of 857 million CNY, a decrease of 39.64% year-on-year, and a net profit attributable to shareholders of -87.2441 million CNY, down 55.72% year-on-year [2] - The company has not distributed any dividends in the last three years, with a total payout of 27.0741 million CNY since its A-share listing [3] Group 3: Shareholder Information - As of December 10, the number of shareholders for Sely Medical is 70,400, a decrease of 11.22% from the previous period, with an average of 2,986 circulating shares per person, an increase of 12.64% [2] - Notable institutional shareholders include Caifutong Advantage Industry Rotation Mixed Fund, which increased its holdings by 58.48% to 1.2282 million shares, and new entrants such as GF Healthcare Stock A and others [3]

Group 1 - The core viewpoint of the news is that Innovation Medical has shown significant stock performance and trading activity, with a year-to-date increase of 169.97% in stock price and notable trading volumes [1][2] - As of December 24, the stock price reached 21.49 CNY per share, with a total market capitalization of 9.483 billion CNY and a trading volume of 302 million CNY [1] - The company has seen a net inflow of 15.23 million CNY from major funds, indicating strong investor interest [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75%, while the average number of circulating shares per person decreased by 37.01% [2] - For the period from January to September 2025, the company reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to the parent company was 4.7244 million CNY, reflecting a significant increase of 116.97% [2] Group 3 - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, but there have been no dividend distributions in the past three years [3]